Live Feeds
● TRACKER Updated 18d ago · 10 sources tracked

FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease

The FDA has approved Rasonque, a once-daily pill from Revolution Medicines, for treating advanced pancreatic cancer. The drug targets the RAS protein, which drives 95% of pancreatic adenocarcinoma cases. Rasonque provides a treatment option for patients after chemotherapy fails and has demonstrated the ability to nearly double patient survival rates.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (12)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The FDA approved Rasonque for treating advanced pancreatic cancer.
  • ✓ Rasonque targets the RAS protein, which drives 95% of pancreatic adenocarcinoma cases.
  • ✓ Rasonque nearly doubles median survival to 13.2 months versus 6.7 months with chemotherapy.
  • ✓ The approval was granted more than six months ahead of schedule.
🛡️ Source Corroboration: 10 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

The FDA approved Rasonque more than six months ahead of schedule based on trials showing it extended median survival.

Live updates

  1. FDA Approves Rasonque for Advanced Pancreatic Cancer

    The FDA has approved Rasonque, a once-daily pill from Revolution Medicines, for treating advanced pancreatic cancer. The drug targets the RAS protein, which drives 95% of pancreatic adenocarcinoma cases. Rasonque provides a treatment option for patients after chemotherapy fails and has demonstrated the ability to nearly double patient survival rates.

    Why it matters

    Pancreatic cancer is one of the deadliest forms of cancer. The approval marks a significant milestone in the treatment of this disease, potentially transforming the standard of care for U.S. patients. For decades, a diagnosis of metastatic pancreatic cancer left patients and physicians facing limited options and difficult treatments.

    What is confirmed

    • The FDA approved Rasonque for treating advanced pancreatic cancer.
    • Rasonque targets the RAS protein, which drives 95% of pancreatic adenocarcinoma cases.
    • Rasonque nearly doubles median survival to 13.2 months versus 6.7 months with chemotherapy.
    • The approval was granted more than six months ahead of schedule.

    What to watch next

    • Future studies on Rasonque's long-term effects
    • Potential expansion of Rasonque's use to earlier stages of pancreatic cancer
    • Impact of Rasonque on the standard of care for pancreatic cancer patients
    Sources used for this update (5)
    1. www.yahoo.com — FDA approves breakthrough cancer drug months ahead of schedule: ‘Unprecedented results’
    2. www.yahoo.com — Groundbreaking pancreatic cancer drug approved by FDA: What we know
    3. www.usatoday.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
    4. medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
    5. www.gastroenterologyadvisor.com — FDA Approves First Pill to Extend Survival In Advanced Pancreatic Cancer
    confidence 100%

  2. FDA Approves Rasonque for Advanced Pancreatic Cancer

    The FDA approved Rasonque, a once-daily pill from Revolution Medicines, for treating advanced pancreatic cancer on Wednesday, August 26, 2026. The drug targets the RAS protein, which drives 95% of pancreatic adenocarcinoma cases. Rasonque provides a treatment option for patients after chemotherapy fails and has demonstrated the ability to nearly double patient survival rates. This approval marks a significant milestone for one of the deadliest forms of cancer, potentially transforming the standard of care for U.S. patients.

    Why it matters

    Pancreatic adenocarcinoma is characterized by high mortality rates and limited treatment options. By targeting the RAS protein, this medication addresses a primary driver of the disease. The approval may also increase investor and clinical interest in similar RAS-targeting assets.

    What is confirmed

    • The FDA approved a new drug for advanced pancreatic cancer on Wednesday.
    • Rasonque is a once-daily pill developed by Revolution Medicines.
    • The drug targets the RAS protein, which is present in 95% of pancreatic adenocarcinoma cases.
    • Rasonque is intended for use after chemotherapy has failed.

    Still unconfirmed

    • Patient survival rates nearly double with the use of Rasonque.
    • The drug is poised to transform the care of pancreatic cancer.

    What to watch next

    • Clinical data on long-term survival rates for Rasonque patients
    • FDA approval or trial results for rival RAS-targeting assets
    Sources used for this update (7)
    1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
    2. The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
    3. Axios — A major RAS drug milestone could spur interest in rival assets
    4. The Hill — FDA approves groundbreaking new pancreatic cancer drug
    5. Bloomberg — A Breakthrough Pancreatic Cancer Drug Marks a New Era for Treatment
    6. www.yahoo.com — FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
    7. www.chicagotribune.com — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community